首页 > 市场调查报告书 > 製药

基因治疗学和RNAi

mRNA疗法市场规模、份额和成长分析（按类型、应用、最终用户和地区划分）—2026-2033年产业预测

市场调查报告书

商品编码

1904270

mRNA疗法市场规模、份额和成长分析（按类型、应用、最终用户和地区划分）—2026-2033年产业预测

mRNA Therapeutics Market Size, Share, and Growth Analysis, By Type (Prophylactic, Therapeutic), By Application (Infectious Diseases, Oncology), By End-user, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月23日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，mRNA 疗法市场规模将达到 117.2 亿美元，到 2025 年将达到 124.8 亿美元，到 2033 年将达到 206.5 亿美元，在预测期（2026-2033 年）内复合年增长率为 6.5%。

市场趋势表明，基于mRNA的疗法正成为治疗慢性疾病的有力解决方案，推动该领域强劲成长。与DNA疫苗相比，mRNA疫苗在生产和分销方面均具有优势，使其成为医疗保健领域更安全的选择。尤其是在新冠肺炎疫情期间，由Moderna和辉瑞-BioNTech等主要企业主导的成功人体临床试验进一步加速了这类疗法的需求。此外，正在进行的肿瘤临床试验表明，人们对mRNA在感染疾病以外的应用也越来越感兴趣。 mRNA稳定性、翻译和递送技术的进步证实了其潜力，使其成为个人化医疗的变革性工具，并重新定义了医疗保健标准，从而进一步推动了未来市场对mRNA产品的需求。

mRNA疗法市场驱动因素

mRNA技术的出现彻底改变了疫苗研发格局，尤其是在感染疾病领域。 mRNA疫苗的快速发展和成功应用，展现了其作为应对健康危机的高效解决方案的巨大潜力。这种创新方法能够对新出现的病原体做出快速反应，体现了mRNA疗法的多功能性和适应性。因此，人们对mRNA技术的兴趣和投资激增，使其成为持续对抗各种感染疾病的关键组成部分，并最终推动了mRNA疗法市场的成长和扩张。

限制mRNA疗法市场的因素

mRNA疗法市场面临许多重大挑战，尤其是在生产和分销环节。其中一个主要障碍在于，如何在确保稳定高效供应链的同时，扩大mRNA产能。全球健康危机进一步加剧了这个问题，凸显了基础设施和物流的脆弱性。因此，该领域的企业必须在满足日益增长的mRNA治疗方法需求的同时，应对复杂的监管环境，并克服采购高品质原料的重重困难。这些因素共同阻碍因素了市场的整体成长潜力。

mRNA治疗药物市场趋势

mRNA疗法市场正经历显着的上升趋势，尤其是在mRNA癌症疫苗的研发方面，这些疫苗正在革新肿瘤治疗领域。这些创新疫苗利用人体自身的细胞机制来诱发针对癌细胞的强效免疫反应，从而有望实现更个人化、更有效的治疗。随着该领域研究的不断深入，生物技术公司与学术机构之间的合作日益加强，加速了创新进程，并改善了临床试验结果。这种不断变化的模式为投资和患者照护的进步提供了巨大的机会，并将mRNA技术定位为未来癌症治疗的基础。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较

主要企业简介

Lonza Group（Switzerland）
Samsung Biologics（South Korea）
Fujifilm Diosynth Biotechnologies（Japan）
Catalent（United States）
BioNTech（Germany）
Ionis Pharmaceuticals（United States）
WuXi Biologics（China）
CordenPharma（Germany）
WuXi AppTec（China）
Boehringer Ingelheim（Germany）
Samsung Biologics（South Korea）
WuXi Biologics（China）
WuXi AppTec（China）
Boehringer Ingelheim（Germany）
WuXi Biologics（China）
WuXi AppTec（China）
Boehringer Ingelheim（Germany）
WuXi Biologics（China）
WuXi AppTec（China）
Boehringer Ingelheim（Germany）

结论与建议

简介目录

Product Code: SQMIG35A2547

mRNA Therapeutics Market size was valued at USD 11.72 Billion in 2024 and is poised to grow from USD 12.48 Billion in 2025 to USD 20.65 Billion by 2033, growing at a CAGR of 6.5% during the forecast period (2026-2033).

Market insights indicate that mRNA-based therapeutics are emerging as powerful solutions for chronic conditions, driving robust growth in this sector. Compared to DNA vaccines, mRNA vaccines offer advantages in both production and distribution, establishing a safer alternative in the healthcare landscape. The successful outcomes of human clinical trials have further fueled demand for these therapeutics, particularly during the COVID-19 pandemic, largely influenced by key players like Moderna and Pfizer-BioNTech. Additionally, ongoing oncology clinical trials highlight an expanding interest in mRNA applications beyond infectious diseases. Technological advancements in stability, translation, and delivery of mRNA underscore its potential, positioning it as a transformative tool in personalized medicine and redefining healthcare standards, thus elevating future market demand for mRNA products.

Top-down and bottom-up approaches were used to estimate and validate the size of the mRNA Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

mRNA Therapeutics Market Segments Analysis

Global mRNA Therapeutics Market is segmented by Type, Application, End-user and region. Based on Type, the market is segmented into Prophylactic and Therapeutic. Based on Application, the market is segmented into Infectious Diseases, Oncology, Rare Genetic Diseases,respiratory diseasesand Others. Based on End-user, the market is segmented into Hospitals & Clinics, Research Organizations and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the mRNA Therapeutics Market

The emergence of mRNA technology has significantly transformed the landscape of vaccine development, particularly in the context of infectious diseases. The rapid advancement and successful deployment of mRNA vaccines have demonstrated their potential as highly effective and efficient solutions to health crises. This innovative approach offers a swift response to emerging pathogens, showcasing the versatility and adaptability of mRNA therapeutics. As a result, the interest and investment in mRNA technology have surged, positioning it as a vital component in the ongoing fight against various infectious diseases, ultimately driving growth and expansion within the mRNA therapeutics market.

Restraints in the mRNA Therapeutics Market

The mRNA therapeutics market faces several significant challenges, particularly related to the production and distribution processes. One of the primary obstacles is the difficulty in scaling up production capacity for mRNA while ensuring a stable and efficient supply chain. This issue has been exacerbated by global health crises, which have highlighted vulnerabilities in infrastructure and logistics. As a result, companies in this sector must navigate complex regulatory landscapes and manage the intricacies of sourcing high-quality materials, all while striving to meet the increasing demand for mRNA-based therapies. These factors contribute to the overall restraint in the market's growth potential.

Market Trends of the mRNA Therapeutics Market

The mRNA therapeutics market is experiencing a significant upward trend, particularly in the development of mRNA cancer vaccines, which are revolutionizing oncology. These innovative vaccines harness the body's own cellular machinery to elicit robust immune responses against cancer cells, offering the potential for more personalized and effective treatments. As research in this area expands, the collaboration between biotech firms and academic institutions is intensifying, leading to accelerated innovation and enhanced clinical trial outcomes. This evolving landscape presents substantial opportunities for investment and advancements in patient care, positioning mRNA technology as a cornerstone in the future of cancer therapeutics.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Analysis
Patent Analysis

Global mRNA Therapeutics Market Size by Type & CAGR (2026-2033)

Market Overview
Prophylactic
Therapeutic

Global mRNA Therapeutics Market Size by Application & CAGR (2026-2033)

Market Overview
Infectious Diseases
Oncology
Rare Genetic Diseases
Respiratory Diseases
Others

Global mRNA Therapeutics Market Size by End-user & CAGR (2026-2033)

Market Overview
Hospitals & Clinics
Research Organizations
Others

Global mRNA Therapeutics Market Size & CAGR (2026-2033)

North America (Type, Application, End-user)
- US
- Canada
Europe (Type, Application, End-user)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Application, End-user)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Application, End-user)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Application, End-user)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Lonza Group (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Samsung Biologics (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fujifilm Diosynth Biotechnologies (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Catalent (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioNTech (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ionis Pharmaceuticals (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
WuXi Biologics (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CordenPharma (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
WuXi AppTec (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Samsung Biologics (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
WuXi Biologics (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
WuXi AppTec (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
WuXi Biologics (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
WuXi AppTec (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
WuXi Biologics (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
WuXi AppTec (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments